Concomitant External-beam Irradiation and Chemotherapy Followed by High-dose Rate Brachytherapy Boost in the Treatment of Squamous Cell Carcinoma of the Vagina: A Single-Center Retrospective Study.
AIM
To assess the outcome of 35 patients with vaginal carcinoma treated with different radiotherapy modalities.


MATERIALS AND METHODS
Thirty-one patients received external-beam irradiation (EBRT) to the entire vagina, para-vaginal area and pelvic nodes (total dose=45-50.4 Gy). Concomitant chemotherapy was used in 22 patients. Nineteen patients received additional 15-25 Gy high-dose-rate brachytherapy (BT) boost and eight received additional EBRT boost to the primary tumor site. Four women received exclusive 30-40 Gy high-dose-rate BT.


RESULTS
Median progression-free survival and median overall survival were 22 months and 89 months, respectively. Age <70 years, use of EBRT plus BT, and concomitant chemotherapy were associated with better progression-free (p=0.002, p=0.007, and p=0.02) and overall (p=0.01, p=0.009, p=0.009) survival.


CONCLUSION
Concomitant EBRT and chemotherapy followed by BT is the best treatment for vaginal carcinoma.
['Laliscia|Concetta|C|', 'Fabrini|Maria Grazia|MG|', 'Delishaj|Durim|D|', 'Coraggio|Gabriele|G|', 'Morganti|Riccardo|R|', 'Tana|Roberta|R|', 'Paiar|Fabiola|F|', 'Gadducci|Angiolo|A|']
D000328:Adult D000368:Aged D000369:Aged, 80 and over D000970:Antineoplastic Agents D001918:Brachytherapy D016190:Carboplatin D002294:Carcinoma, Squamous Cell D059248:Chemoradiotherapy D002945:Cisplatin D005260:Female D005472:Fluorouracil D006801:Humans D008875:Middle Aged D017239:Paclitaxel D012189:Retrospective Studies D014625:Vaginal Neoplasms
chemotherapy brachytherapy Vaginal carcinoma external beam radiation recurrence